Your session is about to expire
← Back to Search
HPN217 for Multiple Myeloma
Study Summary
This trial is testing a new drug to see if it is safe and tolerated by patients with a certain type of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from the side effects of my previous treatments.I have another cancer besides the one being treated, but it's either in remission for less than 3 years or is a low-risk type.I had a stem cell or bone marrow transplant less than 3 months ago.You have an autoimmune disease, except for certain conditions like vitiligo, resolved childhood eczema, or thyroid problems that are under control. If you haven't had treatment for your autoimmune disorder in the past 3 years, you may be able to participate after talking with the study doctor.I've had 3 treatments for myeloma, including specific drugs, and can't tolerate or am not eligible for other beneficial treatments.I had a stem cell or organ transplant over a year ago and am not on immunosuppressants.My condition is either plasma cell leukemia or non-secretory myeloma.I am 18 years old or older.My multiple myeloma has returned outside the bone marrow without measurable disease.You have a certain amount of abnormal proteins in your blood or urine that can be measured.My multiple myeloma has returned or didn't respond well to treatment.
- Group 1: HPN217 dose escalation with extended dosing intervals
- Group 2: HPN217 monotherapy dose escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment currently available for this research endeavor?
"As per the clinicaltrials.gov registry, this medical trial is currently enlisting volunteers and has been modified most recently on July 21st 2022 since its initial announcement in March of 2020."
What is the current enrollment size of this clinical investigation?
"In order for this clinical trial to commence, Harpoon Therapeutics must recruit 70 suitable candidates. These participants will be enrolled from Swedish Medical Center in Seattle and Banner MD Anderson Cancer Centre in Gilbert, Arizona."
What potential risks exist for patients taking HPN217?
"Applying a scale of 1-3, our analysts at Power believe HPN217's safety to be an estimated score of 1 due to the restricted amount of supporting evidence for its efficacy and security."
Is this research project enrolling individuals above the age of eighty-five?
"According to the criteria for eligibility, potential participants in this clinical trial should have a minimum age of 18 and an upper limit of 100 years old."
What criteria must an individual meet to be eligible for the clinical trial?
"This trial is recruiting 70 participants, ranging from 18 to 100 years old, with documented RRMM and a serum M-protein count of 0.5 g/dL or higher. Other requirements include having received at least 3 prior treatments (including proteasome inhibitor therapy and immune modulatory drug treatment), an abnormal FLC ratio (<0.26 or >1.65) and resolution of any acute effects to baseline severity according to CTCAE version 5.0 Grade ≤1 standards"
Share this study with friends
Copy Link
Messenger